Immunogenicity of idursulfase and clinical outcomes in very young patients (16 months to 7.5 years) with mucopolysaccharidosis II (Hunter syndrome)
Open Access
- 24 April 2015
- journal article
- clinical trial
- Published by Springer Science and Business Media LLC in Orphanet Journal of Rare Diseases
- Vol. 10 (1), 1-14
- https://doi.org/10.1186/s13023-015-0265-2
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Development of a panel of highly sensitive, equivalent assays for detection of antibody responses to velaglucerase alfa or imiglucerase enzyme replacement therapy in patients with Gaucher diseaseJournal of Immunological Methods, 2011
- The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: Lessons learned from infantile Pompe diseaseGenetics in Medicine, 2011
- Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndromeGenetics in Medicine, 2011
- Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infantsMolecular Genetics and Metabolism, 2010
- A retrospective analysis of the potential impact of IgG antibodies to agalsidase β on efficacy during enzyme replacement therapy for Fabry diseaseMolecular Genetics and Metabolism, 2009
- Recognition and Diagnosis of Mucopolysaccharidosis II (Hunter Syndrome)Pediatrics, 2008
- Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeuticsJournal of Immunological Methods, 2007
- A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome)Genetics in Medicine, 2006
- THE NATURAL HISTORY OF THE SEVERE FORM OF HUNTER'S SYNDROME: A STUDY BASED ON 52 CASESDevelopmental Medicine and Child Neurology, 1983
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958